Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Probiotics, Fatty Acids Are Case Studies In IoM Infant Formula Report

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

New infant formula ingredients should undergo a two-step evaluation process to evaluate potential toxicity, the Institute of Medicine recommends in a report released March 1. The report outlines details the addition of fatty acids and probiotics as case studies

You may also be interested in...



Martek Says IoM Report On Infant Formula Will Not Impact Sales

Recommendations in the Institute of Medicine's recent report on evaluating new infant formula ingredients will not affect currently marketed products containing Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA)

Martek Says IoM Report On Infant Formula Will Not Impact Sales

Recommendations in the Institute of Medicine's recent report on evaluating new infant formula ingredients will not affect currently marketed products containing Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA)

Martek Says IoM Report On Infant Formula Will Not Impact Sales

Recommendations in the Institute of Medicine's recent report on evaluating new infant formula ingredients will not affect currently marketed products containing Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA)

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS096565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By